Corcept Therapeutics CORT 深 沪
已收盘 09-26 16:00:00 美东时间
83.87
+1.140
+1.38%
华盛通- 最 高84.89
- 今 开83.81
- 成交量 48.28万股
- 最 低 82.78
- 昨 收 82.73
- 总市值 88.06亿
- 52周最高 117.33
- 市盈率 静 68.12
- 换手率 0.46%
- 52周最低 42.01
- 委 比 59.87%
- 总股本 1.05亿
- 历史最高 117.33
- 量 比 0.36
- 振 幅 2.55%
- 历史最低 1.27
- 每 手 1
- 风险率 10.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Corcept Therapeutics To Present New Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer At 2025 ESMO
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
09-23 02:31
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Corcept's ovarian cancer treatment under FDA review
Corcept Therapeutics (NASDAQ:CORT) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment of platinum-resistant ovarian cancer. The agency h...
09-10 20:51
Corcept Therapeutics’ New Drug Application Accepted by FDA
Corcept Therapeutics ( ($CORT) ) just unveiled an announcement. On September 10...
09-10 20:29
FDA Accepts Corcept's NDA For Relacorilant In Platinum-Resistant Ovarian Cancer, Sets PDUFA Date For July 11, 2026
FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat
09-10 20:08
Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension
Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical st...
08-08 00:29
A Look at Axsome Therapeutics's Upcoming Earnings Report
Axsome Therapeutics (NASDAQ:AXSM) is preparing to release its quarterly earning...
08-02 01:04
Piper Sandler Maintains Overweight on Corcept Therapeutics, Lowers Price Target to $121
Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and lowers the price target from $131 to $121.
08-01 20:08
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
